title: The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B.
abstract: OBJECTIVE
  Recurrent malignant meningiomas and unresectable meningiomas represent a great therapeutic challenge after the failure of radiation therapy. No effective chemotherapy has been found. We report the preliminary results of the treatment of patients with recurrent unresectable or malignant meningiomas with recombinant interferon alpha-2B (IFN-alpha-2B).
  
  
  METHODS
  Each of six patients with either a recurrent malignant meningioma or an unresectable meningioma was treated with IFN-alpha, administered subcutaneously at a dosage of 4 mU/m2 per day, 5 days per week. Two of the six meningiomas were regular, one was atypical, and three were malignant.
  
  
  RESULTS
  Five of six patients exhibited positive response to treatment; with stabilization of the size of the tumor in four patients and slight regression in one. The responses observed lasted from 6 to 14 months. The toxicity associated with prolonged use of IFN-alpha was mild and well tolerated.
  
  
  CONCLUSIONS
  These results suggest that IFN-alpha is effective in the treatment of recurrent malignant meningiomas.
authors.affiliation: Department of Neuro-Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, USA.
authors.forename: S E
authors.initials: SE
authors.lastname: Kaba
authors.forename: F
authors.initials: F
authors.lastname: DeMonte
authors.forename: J M
authors.initials: JM
authors.lastname: Bruner
authors.forename: A P
authors.initials: AP
authors.lastname: Kyritsis
authors.forename: K A
authors.initials: KA
authors.lastname: Jaeckle
authors.forename: V
authors.initials: V
authors.lastname: Levin
authors.forename: W K
authors.initials: WK
authors.lastname: Yung
mesh_terms: D000328:Adult; D000368:Aged; D001921:Brain / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008279:Magnetic Resonance Imaging; D008297:Male; D008577:Meningeal Neoplasms / Q000473:pathology / Q000628:therapy*; D008579:Meningioma / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins